CanWell Pharma’s First-in-Class innovative drug CAN2109 granted IND approval by China National Medical Products Administration (NMPA)
CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted IND approval by the China National Medical Products Administration (NMPA). CanWell plans to immediately initiate the patient enrollment to evaluate CAN2109’s safety, PK, PD and clinical activity for the treat…
CanWell’s CAN2109 IND Granted Approval by US FDA
CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted clinical approval by the US Food and Drug Administration (FDA) and it will soon conduct Phase I clinical trial for various solid tumors. CAN2109 is a novel long-acting Immunogenic cell death (ICD) inducer, whi…
Canwell to Present CAN1012 Research Update at the 4th STING & TLR Targeting Therapies Summit
CanWell announced today that the preclinical research results and clinical plan of the company’s TLR7 agonist CAN1012 would be presented at the 4th STING & TLR Targeted Therapy Summit in 2023. CAN1012 is a highly selective small-molecule TLR7 agonist developed by CanWell with global intell…
CanWell was Invited to Present at 9th Immuno-oncology 360° (IO360°) Conference
CanWell presented the preclinical research results of CAN1012, a small molecule TLR7 agonist in the form of an oral presentation at the 9th Immuno-oncology 360° (IO360°) conference. The IO360° conference is a globally renowned annual conference for cancer immunotherapy, providing a collaboration opp…
CanWell presented the preclinical research results of CAN1012 at the annual meeting of the Society for Immunotherapy of Tumors (SITC)
CanWell announced today that the preclinical results of its small molecule TLR7 agonist CAN1012 were presented at the 37th Annual Meeting of the Society for Immunotherapy of Tumors (SITC 2022, Boston). Abstract ID: #1171 Poster title: CAN1012: A SELECTIVE AND POTENT TLR7 AGONIST WITH STRONG ANTITUMO…
First patient dosed in CanWell’s CAN1012 Ph1 Trial in China
CanWell Biotech Ltd. , a company specializing in the development of innovative immune-oncology drugs, announced today that the 1st patient has been successfully dosed in its ongoing CAN1012 Ph1 clinical trial in China. The CAN1012 Phase I clinical trial is an open-label, multicenter, dose-escalation…
CanWell’s TLR7 Agonist CAN1012 Received IND Approval by CDE in China
Canwell announced today that its TLR7 agonist CAN1012 had obtained clinical trial approval from China’s Center for Drug Evaluation (CDE). The approval allows CanWell to conduct Phase I clinical trials targeting advanced solid tumors in China. Prior to this, CAN1012 had obtained Phase I clinica…
CanWell’s TLR7 Agonist CAN1012 IND Granted Approval by US FDA
CanWell Pharma announced that its First-in-Class innovative drug, TLR7 agonist CAN1012, has been granted clinical approval by the US Food and Drug Administration (FDA) and will soon conduct Phase I clinical trials for various solid tumors. CAN1012 is an innovative Toll-like receptor (TLR) 7 small mo…